PF 6678552

Drug Profile

PF 6678552

Alternative Names: PF-06678552; PF-6678552

Latest Information Update: 04 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antihyperlipidaemics; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hypercholesterolaemia

Most Recent Events

  • 07 Aug 2014 Discontinued - Phase-I for Hypercholesterolaemia (In volunteers) in Belgium (PO)
  • 29 Jul 2014 Pfizer completes a phase I trial in Healthy volunteers in Belgium (NCT02079922)
  • 01 Apr 2014 Pfizer initiates enrolment in a phase I trial in Healthy volunteers in Belgium (NCT02079922)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top